上海打出“组合拳”，促进医保商保共同发展支持创新药械

Group 1 - The core viewpoint of the news is the introduction of measures by the Shanghai Financial Regulatory Bureau to promote the high-quality development of commercial health insurance, enhancing the insurance industry's ability to serve public health needs and improving the accessibility and affordability of innovative drugs and medical devices [1][2] - The measures include five main areas with 18 specific actions aimed at broadening the coverage of commercial health insurance and enriching product forms, particularly focusing on developing commercial nursing insurance and a multi-tiered product system [1] - There is an emphasis on encouraging the development of health insurance products tailored for specific groups such as the elderly and those with chronic conditions, as well as enhancing health management services to reduce risks [1][2] Group 2 - The measures advocate for the creation of group health insurance products that involve employer contributions, covering innovative drug and device costs, and aligning with basic medical insurance for seamless settlement [1][2] - There is a push for deepening the interconnectivity of medical, health insurance, and commercial insurance data, using clinical trial data as pricing references for insurance companies, and supporting a "one-stop" settlement service [2] - The introduction of innovative payment mechanisms for new drugs and devices is encouraged, facilitating their integration into hospitals and insurance coverage, while also promoting tax deductions and optimized funding to support the growth of commercial health insurance [2]